Keyword: Frequency Therapeutics
The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.
Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.
A safety study of Frequency Therapeutics’ hearing loss drug treatment has cleared its first hurdles while showing some signs of hearing improvement.
MassBio's Project Onramp matches low-income students from across Massachusetts to well-paid summer internships at local biotech companies.
Decibel just transformed itself into a clinical-stage biotech by licensing a phase 1 candidate from Seattle startup Oricula Therapeutics.
Frequency Therapeutics has just raised $32 million in a financing round it hopes will help it bring its therapy for noise-induced hearing loss into the clinic.